In a mouse model of liver cancer in an in vivo study, p53 downregulated expression of mevalonate-involved gene products, which included Mevalonate Kinase (MVK), farnesyl-diphosphate farnesyltransferase 1 (FDFT1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) in premalignant hepatocytes, thus suppressing tumour growth. The gene discussed is MVK; the disease is liver cancer.